Cambridge Healthtech Training Seminars offer real-life case studies, problems encountered and solutions applied, and extensive coverage of the basic science underlying each topic. Experienced Training Seminar instructors offer a mix of formal lectures,
interactive discussions and activities to help attendees maximize their learning experiences. These immersive trainings will be of value to scientists from industry and academic research groups who are entering new fields – and to those working
in supporting roles that will benefit from an in-depth briefing on a specific aspect of the industry.
TS2A: Applying Pharmacology to New Drug Discovery: The System-Independent Quantification of Molecular Drug Properties for Prediction of Therapeutic Utility
The Westin Copley Place | Boston, MA
Tuesday, June 19 - Wednesday, June 20
Day 1: 9:00 am – 5:00 pm | Day 2: 9:00 am – 12:00 pm
Helicon
Instructor:
Terry Kenakin, PhD, Professor, Department of Pharmacology, University of North Carolina School of Medicine
Over the past six years, the primary cause of new drug candidate failures (50%) has been failure of therapeutic
efficacy. Put another way, drug discovery programs do everything right, get the defined candidate molecule, only to have it fail in therapeutic trials. Among the most prevalent reasons proposed for this shortcoming is the lack of translation of in
vitro and recombinant drug activity to therapeutic in vivo whole systems. Drug activity in complete systems can be characterized with the application of pharmacological principles which translate drug behaviors in various organs with molecular scales
of affinity and efficacy.
Pharmacological techniques are unique in that they can convert descriptive data (what we see, potency, activity in a given system) to predictive data (molecular scales of activity that can be used to predict activity in all systems including the therapeutic
one, i.e. affinity, efficacy). The predicted outcome of this process is a far lower failure rate as molecules are progressed toward clinical testing.
This course will describe pharmacological principles and procedures to quantify affinity, efficacy, biased signaling and allostery to better screen for new drugs and characterize drug candidates in lead optimization assays. In particular, new concepts
that have entered the fabric of discovery over the past few years, namely biased signaling and allosteric drug function, will be emphasized as new ways forward to reduce new candidate attrition in the drug discovery process.
Topics to be Covered in the Seminar:
COURSE OUTLINE:
Day 1 PM:
1. New Drug Discovery Infrastructure: Strategies- vs Target- vs Systems-Based, Discovery Teams, Target Selection
2. Cellular Activation (agonism): Affinity and Efficacy, Potency,
Biased Signaling, Selectivity, Screening for Agonists
Day 2 AM:
1. Antagonism: Orthosteric (competitive, non-competitive, hemi-equilibria), Partial Agonism, Screening for Antagonists
2. Inverse
Agonism
3. Allosteric Modulation, PAMs, NAMs, Screening for Allosterics
4. Candidate Selection: Real Time Kinetics and in vivo Target Coverage
Day 2 PM: Drug Development
1. Pharmacokinetics:
Druglike Character, in vivo Absorption, Distribution, Metabolism
2. Excretion, in vivo PK, Non-Linear PK
3. Safety Pharmacology: Safety vs. Toxicity Risk Benefit Analyses
COURSE MATERIAL:
Summary sheets, exercises with answers, relevant papers are included as well as a PDF of all slides. The course is based on the book A Pharmacology Primer: Techniques
for More Effective and Strategic Drug Discovery. 4th Edition, Elsevier/Academic Press, 2014. The table of contents of this book can be viewed at: www.amazon.com/Pharmacology‐Primer‐Fourth‐Edition‐Techniques/
INSTRUCTOR BIOGRAPHY:
Terry Kenakin, PhD, Professor, Department of Pharmacology, University of North Carolina School of Medicine
Dr. Kenakin has 32 years of experience in drug industry (7 at Burroughs-Wellcome and 25 at GlaxoSmithKline) as a project leader and lead optimization pharmacologist. The course is based on the book A Pharmacology Primer: Techniques for More Effective
and Strategic Drug Discovery written by the instructor (Elsevier/Academic Press, 4th edition, 2014, pp 1-450).
Training Seminar Information
Each CHI Training Seminar offers 1.5 days of instruction with start and stop times for each day shown above and on the Event-at-a-Glance published in the onsite Program & Event Guide. Training Seminars will include morning and afternoon refreshment
breaks, as applicable, and lunch will be provided to all registered attendees on the full day of the class.
Each person registered specifically for the training seminar will be provided with a hard copy handbook for the seminar in which they are registered. A limited number of additional handbooks will be available for other delegates who wish to attend the
seminar, but after these have been distributed, no additional books will be available.
Though CHI encourages track hopping between conference programs, we ask that Training Seminars not be disturbed once they have begun. In the interest of maintaining the highest quality learning environment for Training Seminar attendees, and because Seminars
are conducted differently than conference programming, we ask that attendees commit to attending the entire program, and not engage in track hopping, as to not disturb the hands-on style instruction being offered to the other participants.